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Abstract
Background—Brain tissue analysis is necessary to confirm prion diseases. Clinically 
unsuspected cases may be identified through neuropathologic testing.
Methods—National Alzheimer’s Coordinating Center (NACC) Minimum and Neuropathologic 
Data Sets for 1984–2005 were reviewed. Eligible patients had dementia, underwent autopsy, had 
available neuropathologic data, belonged to a currently funded Alzheimer’s Disease Center 
(ADC), and were coded as having an Alzheimer’s disease clinical diagnosis or a non-prion disease 
etiology. For the eligible patients with neuropathology indicating prion disease, further clinical 
information, collected from the reporting ADC, determined whether prion disease was considered 
before autopsy.
Results—Of 6000 eligible patients in the NACC database, 7 (0.12%) were clinically unsuspected 
but autopsy confirmed prion disease cases.
Conclusion—The proportion of dementia patients with clinically unrecognized but autopsy 
confirmed prion disease was small. Besides confirming clinically suspected cases, neuropathology 
is useful to identify unsuspected, clinically atypical cases of prion disease.
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Prion diseases are rare, fatal, neurodegenerative disorders. The most common prion disease, 
Creutzfeldt-Jakob disease (CJD), is characterized by rapidly progressive dementia and has a 
reported incidence of approximately one case per million population per year.1 The illness 
often worsens rapidly, leading to death within one year of onset in the majority of affected 
patients.1,2 While short disease duration may be a distinguishing characteristic of CJD,3 
clinical signs, including dementia and movement disorders, may overlap with much more 
common diagnoses such as Alzheimer’s Disease (AD).
The Centers for Disease Control and Prevention (CDC) conducts surveillance for CJD and 
other prion diseases through several mechanisms2; however, this surveillance may not 
identify prion disease patients misdiagnosed with other neurologic diseases such as AD. 
Furthermore, barriers to autopsy exist that limit the number of suspected prion disease cases 
with neuropathologic testing, although such analyses are necessary to confirm the 
diagnosis.1 To assess the frequency of occurrence of clinically unrecognized prion disease, 
data sets from the National Alzheimer’s Coordinating Center (NACC) were analyzed. 
NACC was established in 1999 by the National Institute on Aging (NIA) to facilitate 
collaborative research among NIA-funded Alzheimer’s Disease Centers (ADCs) across the 
United States. The center developed and maintains a large relational database of 
standardized clinical and neuropathologic research data collected from the ADCs.4
Methods
NACC Minimum (MDS) and Neuropathologic (NPDS) data sets for 1984–2005 were 
extracted and reviewed. The MDS includes demographic data for patients reported to NACC 
as well as their clinical and neuropathological diagnoses. The NPDS contains one record for 
each autopsied patient in the MDS with available autopsy data; detailed information is 
provided about neuropathologic findings and resultant diagnoses.4 For patients with 
contradictory values between the MDS and NPDS, values from the NPDS, which relies on 
more specific criteria, were selected based on NACC’s previous experience with the data 
sets.
To be included in the study, patients had to meet eligibility criteria; patients meeting these 
criteria had dementia, were coded as having either a primary clinical diagnosis of AD or a 
known suspected etiology other than a prion disease, underwent autopsy, had available 
neuropathologic data, and belonged to a currently funded ADC. For eligible patients who 
had neuropathology indicative of prion disease but were coded as having a non-prion disease 
clinical diagnosis, further information was collected via a short form sent to the appropriate 
ADC asking 1) whether a clinical diagnosis of prion disease was mentioned in the patient’s 
medical records (excluding neuropathologic findings) and the type of prion disease 
mentioned, if applicable, and 2) what the neuropathologically-confirmed diagnosis was for 
the patient. Space was also allotted for additional comments. Cases of clinically 
unrecognized prion disease were defined as cases with a neuropathology-confirmed prion 
disease in the absence of a clinical diagnosis of prion disease indicated in the patient’s 
medical records. The percentages of these cases in the database were calculated, with their 
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95% Wilson-corrected confidence intervals (CIs) determined using Stata version 13 
(StataCorp, College Station, TX).
Results
During 1984–2005, 6,000 patients, representing 30 ADCs, met the eligibility criteria (Figure 
1). The median age of the patients was 80 years (interquartile range: 73–86), and 53.3% 
were female. Of the 6,000 patients, 4,642 patients (77.4%) had a clinical diagnosis of AD. 
The remaining patients had clinical diagnoses of other non-prion disease dementing illnesses 
including frontal lobe dementia (5.1%), vascular dementia (3.6%), Parkinson’s disease 
dementia (2.2%), non-Parkinson’s dementia with Lewy bodies (1.9%), progressive 
supranuclear palsy (1.2%), and other dementing illnesses or conditions.
Twenty-four patients (0.4%) were identified with a neuropathology code of prion disease. 
For these 24 patients, further clinical and/or neuropathological information was collected for 
21; attempts to gather information on the remaining three patients were unsuccessful. Two 
of the 21 patients were subsequently reclassified as not autopsy confirmed prion disease 
cases based on information provided by the reporting ADCs indicating that the prion disease 
diagnosis had been miscoded due to misinterpretation of neuropathologic information. The 
remaining 19 patients, representing seven ADCs, included 12 patients for whom a 
premortem prion disease diagnosis based on clinical assessment had been considered. No 
mention of a prion disease diagnosis was found for the other seven patients (Table 1). The 
percentage of clinically unrecognized prion disease cases in the NACC database was 
therefore 0.12% (95% CI 0.06–0.24, seven cases out of 6,000 patients); among patients with 
a clinical diagnosis of AD, the percentage was 0.11% (95% CI 0.05–0.25, five cases out of 
4,642 patients).
Discussion
Generally, CJD and other prion diseases can be recognized by typical clinical manifestations 
and a rapid progression from illness onset to death.1,2 While details on clinical course were 
not collected in the present study, at least three of the seven prion disease patients who were 
not recognized clinically had an illness duration exceeding two years, and three patients 
were <50 years of age; these characteristics, along with other atypical manifestations, may 
have made correct diagnosis more difficult. The lack of a reliable antemortem clinical test 
for prion diseases may have also contributed to the difficulty in diagnosis.5
The authors of a 1989 study reported that 13% of clinically diagnosed AD patients were 
found upon autopsy to actually have CJD.6 Although the sample was small (n=46) and the 
proportion of these patients for whom clinical consideration of a prion disease diagnosis 
may have led to an autopsy was not reported, this finding has repeatedly fueled speculation 
that a substantial proportion of CJD cases are potentially being missed. By comparison, in 
the present study, the proportion of dementia patients with clinically unsuspected but 
autopsy confirmed prion disease was much less; for most years, no such prion disease cases 
were identified. Even if the three cases with a neuropathology code of prion disease for 
whom further information could not be obtained were assumed to be additional 
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unrecognized prion disease cases, the percentage of such cases in the database would only 
increase minimally, from 0.12% to 0.17% (95% CI 0.09–0.31, ten cases out of 6,000 
patients); among patients with a clinical diagnosis of AD, the percentage would also 
increase to 0.17% (95% CI 0.09–0.34, eight cases out of 4,642 patients).
The findings of this study are consistent with a much smaller study (n=22) that did not find 
any prion disease cases upon neuropathological analysis of patients initially diagnosed with 
other disorders.3 On the other hand, authors of other studies have reported that AD and 
additional neurological disorders may be misdiagnosed as prion diseases5,7,8; this is not 
surprising given the findings of one study that found that while most AD cases (90%) met 
AD clinical classification criteria, a high proportion also fulfilled clinical criteria for CJD 
(58%).7 Chitravas et al. retrospectively reviewed pathological findings of cases clinically 
suspected to have prion disease that were negative upon autopsy from the National Prion 
Disease Pathology Surveillance Center (NPDPSC) and reported that many patients who 
were suspected to have prion disease actually suffered from potentially treatable neurologic 
diseases such as immune-mediated disorders, neoplasms, infections, and metabolic or toxic 
encephalopathies.5
A limitation of the present study is that the NACC data sets may not be a representative 
sample of patients diagnosed with AD in the United States. The NACC collects data from 
various centers around the country, each with its own criteria for the inclusion of cases, and 
these specialized centers may be better equipped to provide accurate diagnoses compared to 
other institutions. However, if misdiagnosis of prion disease cases prior to autopsy was 
occurring at a substantial rate, the data sets could potentially reflect that. Furthermore, 
because neuropathologic analyses would be expected to be more commonly performed 
among clinically atypical AD patients, this study, which only included autopsied cases, 
likely overestimates the percentage of clinically unsuspected prion disease cases that would 
be found among the overall AD population. Further limitations of the present study are that 
descriptions of neuropathological diagnoses for patients with a neuropathology code 
indicating prion disease were restricted to what was provided on the short form submitted by 
the ADC, and information on the precise diagnostic techniques applied by the pathologists 
who conducted the brain autopsies in the different ADCs over the 20+ years of the study 
was not available for review. Thus, although brain autopsy results are generally recognized 
as the gold standard for diagnosing prion diseases, it is possible that not all autopsied cases 
of these diseases were ascertained.
Seven decedents, who were identified in the database as having clinically unsuspected prion 
disease, were eventually appropriately classified as having prion disease due to positive 
autopsy findings. The present study therefore underscores the importance of neuropathologic 
testing for all possible prion disease cases, at least until a definitive antemortem, non-brain 
tissue based, diagnostic test becomes established. In addition to confirming clinically 
suspected cases, testing is useful to identify unsuspected, clinically atypical cases. To 
augment national prion disease surveillance, the CDC, in collaboration with the American 
Association of Neuropathologists, established the NPDPSC.9 Personnel at the center 
perform diagnostic testing of suspected prion disease cases in the United States. 
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Neurologists treating patients with possible prion disease are encouraged to use the services 
of the NPDPSC for disease confirmation.
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Flow chart of the evaluation of clinically unsuspected prion disease among patients with 
dementia diagnoses in the National Alzheimer’s Coordinating Center database, 1984–2005
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